{"protocolSection": {"identificationModule": {"nctId": "NCT01059825", "orgStudyIdInfo": {"id": "8835-016"}, "secondaryIdInfos": [{"id": "B1521006", "type": "OTHER", "domain": "Pfizer protocol number"}, {"id": "2009-017131-18", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)", "officialTitle": "A 12-Week, Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-02-24", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2011-01-20", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-01-20", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-01-29", "studyFirstSubmitQcDate": "2010-01-29", "studyFirstPostDateStruct": {"date": "2010-02-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-09-08", "resultsFirstSubmitQcDate": "2017-09-08", "resultsFirstPostDateStruct": {"date": "2017-10-04", "type": "ACTUAL"}, "dispFirstSubmitDate": "2012-11-12", "dispFirstSubmitQcDate": "2012-11-12", "dispFirstPostDateStruct": {"date": "2012-11-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-08-15", "lastUpdatePostDateStruct": {"date": "2018-09-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus. Participants in the study will receive 1 of 6 treatments for 12 weeks including 1 treatment with an approved drug (sitagliptin) for the treatment of Type 2 diabetes mellitus."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Phase 2", "safety and efficacy study with ertugliflozin (PF-04971729, MK-8835)", "Type 2 diabetes mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 375, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days", "interventionNames": ["Drug: Placebo to Ertugliflozin", "Drug: Placebo to Sitagliptin", "Drug: Metformin"]}, {"label": "Ertugliflozin 1 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days", "interventionNames": ["Drug: Placebo to Ertugliflozin", "Drug: Ertugliflozin 1 mg", "Drug: Placebo to Sitagliptin", "Drug: Metformin"]}, {"label": "Ertugliflozin 5 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days", "interventionNames": ["Drug: Placebo to Ertugliflozin", "Drug: Ertugliflozin 5 mg", "Drug: Placebo to Sitagliptin", "Drug: Metformin"]}, {"label": "Ertugliflozin 10 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days", "interventionNames": ["Drug: Placebo to Ertugliflozin", "Drug: Ertugliflozin 5 mg", "Drug: Placebo to Sitagliptin", "Drug: Metformin"]}, {"label": "Ertugliflozin 25 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days", "interventionNames": ["Drug: Placebo to Ertugliflozin", "Drug: Ertugliflozin 25 mg", "Drug: Placebo to Sitagliptin", "Drug: Metformin"]}, {"label": "Sitagliptin 100 mg", "type": "ACTIVE_COMPARATOR", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days", "interventionNames": ["Drug: Placebo to Ertugliflozin", "Drug: Sitagliptin 100 mg", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Placebo to Ertugliflozin", "description": "Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days", "armGroupLabels": ["Ertugliflozin 1 mg", "Ertugliflozin 10 mg", "Ertugliflozin 25 mg", "Ertugliflozin 5 mg", "Placebo", "Sitagliptin 100 mg"]}, {"type": "DRUG", "name": "Ertugliflozin 1 mg", "description": "Tablet, 1 mg, once daily for 84 days", "armGroupLabels": ["Ertugliflozin 1 mg"]}, {"type": "DRUG", "name": "Ertugliflozin 5 mg", "description": "Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days", "armGroupLabels": ["Ertugliflozin 10 mg", "Ertugliflozin 5 mg"]}, {"type": "DRUG", "name": "Ertugliflozin 25 mg", "description": "Tablet, 25 mg, once daily for 84 days", "armGroupLabels": ["Ertugliflozin 25 mg"]}, {"type": "DRUG", "name": "Sitagliptin 100 mg", "description": "Tablet, 100 mg, once daily for 84 days", "armGroupLabels": ["Sitagliptin 100 mg"], "otherNames": ["Januvia\u00ae, Tesavel\u00ae, Xelevia\u00ae, Ristaben\u00ae"]}, {"type": "DRUG", "name": "Placebo to Sitagliptin", "description": "Tablet, matching placebo to 100 mg, once daily for 84 days", "armGroupLabels": ["Ertugliflozin 1 mg", "Ertugliflozin 10 mg", "Ertugliflozin 25 mg", "Ertugliflozin 5 mg", "Placebo"]}, {"type": "DRUG", "name": "Metformin", "description": "Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).", "armGroupLabels": ["Ertugliflozin 1 mg", "Ertugliflozin 10 mg", "Ertugliflozin 25 mg", "Ertugliflozin 5 mg", "Placebo", "Sitagliptin 100 mg"], "otherNames": ["Fortamet\u00ae, Glucophage\u00ae, Glucophage\u00ae XR, Glumetza\u00ae, Riomet\u00ae, Metgluco\u00ae, Glycoran\u00ae"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Baseline Hemoglobin A1c (HbA1c)", "description": "HbA1c is measured as percent.", "timeFrame": "Baseline"}, {"measure": "Change From Baseline in HbA1c at Week 12", "description": "HbA1c is measured as percent. The change from baseline is the Week 12 HbA1c percent minus the Week 0 HbA1c percent (last observation carried forward \\[LOCF\\]).", "timeFrame": "Baseline and Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in HbA1C at Week 2", "description": "HbA1c is measured as percent. The change from baseline is the Week 2 HbA1c percent minus the Week 0 HbA1c percent (LOCF).", "timeFrame": "Baseline and Week 2"}, {"measure": "Change From Baseline in HbA1c at Week 4", "description": "HbA1c is measured as percent. The change from baseline is the Week 4 HbA1c percent minus the Week 0 HbA1c percent (LOCF).", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in HbA1c at Week 8", "description": "HbA1c is measured as percent. The change from baseline is the Week 8 HbA1c percent minus the Week 0 HbA1c percent (LOCF).", "timeFrame": "Baseline and Week 8"}, {"measure": "Baseline Body Weight", "timeFrame": "Baseline"}, {"measure": "Percent Change From Baseline in Body Weight at Week 12", "description": "The percent change from baseline is the (\\[Week 12 body weight minus the Week 0 body weight\\] divided by the Week 0 body weight) X 100 (LOCF).", "timeFrame": "Baseline and Week 12"}, {"measure": "Percent Change From Baseline in Body Weight at Week 2", "description": "The percent change from baseline is the (\\[Week 2 body weight minus the Week 0 body weight\\] divided by the Week 0 body weight) X 100 (LOCF).", "timeFrame": "Baseline and Week 2"}, {"measure": "Percent Change From Baseline in Body Weight at Week 4", "description": "The percent change from baseline is the (\\[Week 4 body weight minus the Week 0 body weight\\] divided by the Week 0 body weight) X 100 (LOCF).", "timeFrame": "Baseline and Week 4"}, {"measure": "Percent Change From Baseline in Body Weight at Week 8", "description": "The percent change from baseline is the (\\[Week 8 body weight minus the Week 0 body weight\\] divided by the Week 0 body weight) X 100 (LOCF).", "timeFrame": "Baseline and Week 8"}, {"measure": "Baseline Systolic Blood Pressure", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.", "timeFrame": "Baseline"}, {"measure": "Change From Baseline in Systolic Blood Pressure at Week 12", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Systolic Blood Pressure at Week 2", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).", "timeFrame": "Baseline and Week 2"}, {"measure": "Change From Baseline in Systolic Blood Pressure at Week 4", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in Systolic Blood Pressure at Week 8", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).", "timeFrame": "Baseline and Week 8"}, {"measure": "Baseline Diastolic Blood Pressure", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.", "timeFrame": "Baseline"}, {"measure": "Change From Baseline in Diastolic Blood Pressure at Week 12", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Diastolic Blood Pressure at Week 2", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).", "timeFrame": "Baseline and Week 2"}, {"measure": "Change From Baseline in Diastolic Blood Pressure at Week 4", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in Diastolic Blood Pressure at Week 8", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).", "timeFrame": "Baseline and Week 8"}, {"measure": "Baseline Fasting Plasma Glucose", "description": "Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "timeFrame": "Baseline"}, {"measure": "Change From Baseline in Fasting Plasma Glucose at Week 12", "description": "The change from baseline is the Week 12 FPG minus the Week 0 fasting plasma glucose (LOCF). Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Fasting Plasma Glucose at Week 2", "description": "The change from baseline is the Week 2 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "timeFrame": "Baseline and Week 2"}, {"measure": "Change From Baseline in Fasting Plasma Glucose at Week 4", "description": "The change from baseline is the Week 4 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "timeFrame": "Baseline and Week 4"}, {"measure": "Change From Baseline in Fasting Plasma Glucose at Week 8", "description": "The change from baseline is the Week 8 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "timeFrame": "Baseline and Week 8"}, {"measure": "Percentage of Participants Achieving HbA1c <7% at Week 12", "description": "Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "timeFrame": "Week 12"}, {"measure": "Percentage of Participants Achieving HbA1C <6.5% at Week 12", "description": "Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "timeFrame": "Week 12"}, {"measure": "Number of Participants Who Experienced an Advere Event (AE)", "description": "An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin.", "timeFrame": "Up to 98 days"}, {"measure": "Number of Participants Who Discontinued Study Medication Due to an AE", "description": "An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin and excludes a temporary discontinuation of study medication.", "timeFrame": "Up to 84 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participants with type 2 diabetes on stable doses of background medicines for management of the diabetes; aged 18-70 years; body mass index between 23-45 kg/m\\^2\n\nExclusion Criteria:\n\n* Participants with type 1 diabetes, heart attack or stroke in last 6-months, uncontrolled blood pressure, significant kidney disease", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "25754396", "type": "RESULT", "citation": "Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015 Jun;17(6):591-598. doi: 10.1111/dom.12460. Epub 2015 Mar 31."}, {"pmid": "34213819", "type": "DERIVED", "citation": "Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of the 375 enrolled participants included in the metformin run-in period, 328 participants were randomized to 1 of 6 treatment groups.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "FG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "FG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "FG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "FG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "FG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}, {"id": "FG006", "title": "Metformin Run-in", "description": "Participants received open-label metformin during the run-in period."}], "periods": [{"title": "Enrolled, Run-in Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "375"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "328"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "47"}]}], "dropWithdraws": [{"type": "Adverse event not related to study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "3"}]}, {"type": "Did not meet entrance criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "14"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "13"}]}, {"type": "Other reason not specified", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "7"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "5"}]}]}, {"title": "Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "54 participants who completed the run-in period were randomized to this treatment group.", "numSubjects": "54"}, {"groupId": "FG001", "comment": "54 participants who completed the run-in period were randomized to this treatment group.", "numSubjects": "54"}, {"groupId": "FG002", "comment": "55 participants who completed the run-in period were randomized to this treatment group.", "numSubjects": "55"}, {"groupId": "FG003", "comment": "55 participants who completed the run-in period were randomized to this treatment group.", "numSubjects": "55"}, {"groupId": "FG004", "comment": "55 participants who completed the run-in period were randomized to this treatment group.", "numSubjects": "55"}, {"groupId": "FG005", "comment": "55 participants who completed the run-in period were randomized to this treatment group.", "numSubjects": "55"}, {"groupId": "FG006", "comment": "Participants who completed run-in were randomized to 1 of 6 treatment groups.", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "50"}, {"groupId": "FG002", "numSubjects": "49"}, {"groupId": "FG003", "numSubjects": "44"}, {"groupId": "FG004", "numSubjects": "47"}, {"groupId": "FG005", "numSubjects": "52"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "11"}, {"groupId": "FG004", "numSubjects": "8"}, {"groupId": "FG005", "numSubjects": "3"}, {"groupId": "FG006", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "4"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Other reason not specified", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Adverse event related to study drug", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Insufficient clinical response", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}]}, {"type": "Adverse event not related to study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}, {"groupId": "FG006", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Of the 375 enrolled participants included in the metformin run-in period, 328 participants were randomized to 1 of 6 treatment groups.", "groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "BG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "BG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "BG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "BG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "BG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}, {"id": "BG006", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "54"}, {"groupId": "BG002", "value": "55"}, {"groupId": "BG003", "value": "55"}, {"groupId": "BG004", "value": "55"}, {"groupId": "BG005", "value": "55"}, {"groupId": "BG006", "value": "328"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "< 18 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}]}]}, {"title": "18-44 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "9"}, {"groupId": "BG005", "value": "13"}, {"groupId": "BG006", "value": "47"}]}]}, {"title": "45-64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "42"}, {"groupId": "BG003", "value": "47"}, {"groupId": "BG004", "value": "39"}, {"groupId": "BG005", "value": "33"}, {"groupId": "BG006", "value": "238"}]}]}, {"title": ">= 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "7"}, {"groupId": "BG005", "value": "9"}, {"groupId": "BG006", "value": "43"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "14"}, {"groupId": "BG003", "value": "24"}, {"groupId": "BG004", "value": "18"}, {"groupId": "BG005", "value": "15"}, {"groupId": "BG006", "value": "115"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "41"}, {"groupId": "BG003", "value": "31"}, {"groupId": "BG004", "value": "37"}, {"groupId": "BG005", "value": "40"}, {"groupId": "BG006", "value": "213"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Baseline Hemoglobin A1c (HbA1c)", "description": "HbA1c is measured as percent.", "populationDescription": "All randomized participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "55"}, {"groupId": "OG003", "value": "55"}, {"groupId": "OG004", "value": "55"}, {"groupId": "OG005", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.08", "spread": "0.14"}, {"groupId": "OG001", "value": "8.01", "spread": "0.17"}, {"groupId": "OG002", "value": "7.88", "spread": "0.13"}, {"groupId": "OG003", "value": "8.13", "spread": "0.17"}, {"groupId": "OG004", "value": "8.30", "spread": "0.16"}, {"groupId": "OG005", "value": "8.24", "spread": "0.15"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in HbA1c at Week 12", "description": "HbA1c is measured as percent. The change from baseline is the Week 12 HbA1c percent minus the Week 0 HbA1c percent (last observation carried forward \\[LOCF\\]).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 12.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.11", "lowerLimit": "-0.25", "upperLimit": "0.04"}, {"groupId": "OG001", "value": "-0.56", "lowerLimit": "-0.69", "upperLimit": "-0.42"}, {"groupId": "OG002", "value": "-0.80", "lowerLimit": "-0.94", "upperLimit": "-0.66"}, {"groupId": "OG003", "value": "-0.73", "lowerLimit": "-0.87", "upperLimit": "-0.58"}, {"groupId": "OG004", "value": "-0.83", "lowerLimit": "-0.98", "upperLimit": "-0.69"}, {"groupId": "OG005", "value": "-0.87", "lowerLimit": "-1.01", "upperLimit": "-0.73"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null hypothesis is that there is no difference between ertugliflozin and placebo on the primary endpoint.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.45", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.65", "ciUpperLimit": "-0.25"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "The null hypothesis is that there is no difference between ertugliflozin and placebo on the primary endpoint.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.69", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.89", "ciUpperLimit": "-0.49"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "The null hypothesis is that there is no difference between ertugliflozin and placebo on the primary endpoint.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.62", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.82", "ciUpperLimit": "-0.42"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "The null hypothesis is that there is no difference between ertugliflozin and placebo on the primary endpoint.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.72", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.93", "ciUpperLimit": "-0.52"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.76", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.97", "ciUpperLimit": "-0.56"}]}, {"type": "SECONDARY", "title": "Change From Baseline in HbA1C at Week 2", "description": "HbA1c is measured as percent. The change from baseline is the Week 2 HbA1c percent minus the Week 0 HbA1c percent (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 2.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 2", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "52"}, {"groupId": "OG002", "value": "49"}, {"groupId": "OG003", "value": "50"}, {"groupId": "OG004", "value": "49"}, {"groupId": "OG005", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "lowerLimit": "-0.08", "upperLimit": "0.07"}, {"groupId": "OG001", "value": "-0.14", "lowerLimit": "-0.21", "upperLimit": "-0.06"}, {"groupId": "OG002", "value": "-0.29", "lowerLimit": "-0.36", "upperLimit": "-0.21"}, {"groupId": "OG003", "value": "-0.22", "lowerLimit": "-0.29", "upperLimit": "-0.15"}, {"groupId": "OG004", "value": "-0.17", "lowerLimit": "-0.25", "upperLimit": "-0.10"}, {"groupId": "OG005", "value": "-0.26", "lowerLimit": "-0.33", "upperLimit": "-0.18"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.049", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.13", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.24", "ciUpperLimit": "-0.03"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.29", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.39", "ciUpperLimit": "-0.18"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.004", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.22", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.32", "ciUpperLimit": "-0.11"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.020", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.17", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.27", "ciUpperLimit": "-0.06"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.25", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.36", "ciUpperLimit": "-0.15"}]}, {"type": "SECONDARY", "title": "Change From Baseline in HbA1c at Week 4", "description": "HbA1c is measured as percent. The change from baseline is the Week 4 HbA1c percent minus the Week 0 HbA1c percent (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.04", "lowerLimit": "-0.13", "upperLimit": "0.06"}, {"groupId": "OG001", "value": "-0.40", "lowerLimit": "-0.50", "upperLimit": "-0.31"}, {"groupId": "OG002", "value": "-0.49", "lowerLimit": "-0.59", "upperLimit": "-0.40"}, {"groupId": "OG003", "value": "-0.48", "lowerLimit": "-0.57", "upperLimit": "-0.38"}, {"groupId": "OG004", "value": "-0.40", "lowerLimit": "-0.49", "upperLimit": "-0.30"}, {"groupId": "OG005", "value": "-0.48", "lowerLimit": "-0.57", "upperLimit": "-0.38"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.37", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.50", "ciUpperLimit": "-0.23"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.45", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.59", "ciUpperLimit": "-0.32"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.44", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.57", "ciUpperLimit": "-0.30"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.36", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.49", "ciUpperLimit": "-0.22"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.44", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.57", "ciUpperLimit": "-0.30"}]}, {"type": "SECONDARY", "title": "Change From Baseline in HbA1c at Week 8", "description": "HbA1c is measured as percent. The change from baseline is the Week 8 HbA1c percent minus the Week 0 HbA1c percent (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 8.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "lowerLimit": "-0.22", "upperLimit": "-0.02"}, {"groupId": "OG001", "value": "-0.57", "lowerLimit": "-0.69", "upperLimit": "-0.45"}, {"groupId": "OG002", "value": "-0.76", "lowerLimit": "-0.88", "upperLimit": "-0.64"}, {"groupId": "OG003", "value": "-0.73", "lowerLimit": "-0.85", "upperLimit": "-0.60"}, {"groupId": "OG004", "value": "-0.75", "lowerLimit": "-0.87", "upperLimit": "-0.62"}, {"groupId": "OG005", "value": "-0.77", "lowerLimit": "-0.89", "upperLimit": "-0.65"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.47", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.64", "ciUpperLimit": "-0.30"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.66", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.83", "ciUpperLimit": "-0.49"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.63", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.80", "ciUpperLimit": "-0.45"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.65", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.82", "ciUpperLimit": "-0.47"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.67", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.84", "ciUpperLimit": "-0.50"}]}, {"type": "SECONDARY", "title": "Baseline Body Weight", "populationDescription": "All randomized participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "55"}, {"groupId": "OG003", "value": "55"}, {"groupId": "OG004", "value": "55"}, {"groupId": "OG005", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "83.78", "spread": "2.37"}, {"groupId": "OG001", "value": "83.44", "spread": "2.57"}, {"groupId": "OG002", "value": "85.74", "spread": "2.82"}, {"groupId": "OG003", "value": "82.28", "spread": "2.93"}, {"groupId": "OG004", "value": "81.81", "spread": "2.34"}, {"groupId": "OG005", "value": "85.52", "spread": "2.61"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Body Weight at Week 12", "description": "The percent change from baseline is the (\\[Week 12 body weight minus the Week 0 body weight\\] divided by the Week 0 body weight) X 100 (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 12.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.75", "lowerLimit": "-1.18", "upperLimit": "-0.32"}, {"groupId": "OG001", "value": "-1.90", "lowerLimit": "-2.32", "upperLimit": "-1.48"}, {"groupId": "OG002", "value": "-2.50", "lowerLimit": "-2.92", "upperLimit": "-2.07"}, {"groupId": "OG003", "value": "-2.90", "lowerLimit": "-3.33", "upperLimit": "-2.47"}, {"groupId": "OG004", "value": "-2.66", "lowerLimit": "-3.10", "upperLimit": "-2.23"}, {"groupId": "OG005", "value": "-0.30", "lowerLimit": "-0.72", "upperLimit": "0.13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.007", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.15", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.75", "ciUpperLimit": "-0.55"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.75", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.35", "ciUpperLimit": "-1.14"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.15", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.76", "ciUpperLimit": "-1.54"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.91", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.52", "ciUpperLimit": "-1.30"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.833", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "0.45", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.15", "ciUpperLimit": "1.06"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Body Weight at Week 2", "description": "The percent change from baseline is the (\\[Week 2 body weight minus the Week 0 body weight\\] divided by the Week 0 body weight) X 100 (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 2.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 2", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "52"}, {"groupId": "OG002", "value": "48"}, {"groupId": "OG003", "value": "50"}, {"groupId": "OG004", "value": "49"}, {"groupId": "OG005", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.24", "lowerLimit": "-0.46", "upperLimit": "-0.02"}, {"groupId": "OG001", "value": "-0.65", "lowerLimit": "-0.87", "upperLimit": "-0.44"}, {"groupId": "OG002", "value": "-1.36", "lowerLimit": "-1.59", "upperLimit": "-1.14"}, {"groupId": "OG003", "value": "-1.14", "lowerLimit": "-1.36", "upperLimit": "-0.92"}, {"groupId": "OG004", "value": "-1.11", "lowerLimit": "-1.33", "upperLimit": "-0.88"}, {"groupId": "OG005", "value": "0.21", "lowerLimit": "-0.01", "upperLimit": "0.43"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.043", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.42", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.73", "ciUpperLimit": "-0.11"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.13", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.44", "ciUpperLimit": "-0.81"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.90", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.22", "ciUpperLimit": "-0.59"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.87", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.18", "ciUpperLimit": "-0.55"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.967", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "0.45", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.14", "ciUpperLimit": "0.76"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Body Weight at Week 4", "description": "The percent change from baseline is the (\\[Week 4 body weight minus the Week 0 body weight\\] divided by the Week 0 body weight) X 100 (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.44", "lowerLimit": "-0.73", "upperLimit": "-0.15"}, {"groupId": "OG001", "value": "-1.20", "lowerLimit": "-1.48", "upperLimit": "-0.92"}, {"groupId": "OG002", "value": "-1.76", "lowerLimit": "-2.04", "upperLimit": "-1.48"}, {"groupId": "OG003", "value": "-1.68", "lowerLimit": "-1.97", "upperLimit": "-1.39"}, {"groupId": "OG004", "value": "-1.52", "lowerLimit": "-1.81", "upperLimit": "-1.23"}, {"groupId": "OG005", "value": "0.01", "lowerLimit": "-0.28", "upperLimit": "0.30"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.008", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.76", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.17", "ciUpperLimit": "-0.36"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.32", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.73", "ciUpperLimit": "-0.91"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.24", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.65", "ciUpperLimit": "-0.83"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward..", "paramType": "Odds Ratio (OR)", "paramValue": "-1.08", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.49", "ciUpperLimit": "-0.67"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.922", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Odds Ratio (OR)", "paramValue": "0.45", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.04", "ciUpperLimit": "0.86"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Body Weight at Week 8", "description": "The percent change from baseline is the (\\[Week 8 body weight minus the Week 0 body weight\\] divided by the Week 0 body weight) X 100 (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 8.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "Percent change", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.62", "lowerLimit": "-0.96", "upperLimit": "-0.28"}, {"groupId": "OG001", "value": "-1.65", "lowerLimit": "-1.98", "upperLimit": "-1.32"}, {"groupId": "OG002", "value": "-2.18", "lowerLimit": "-2.52", "upperLimit": "-1.85"}, {"groupId": "OG003", "value": "-2.30", "lowerLimit": "-2.64", "upperLimit": "-1.96"}, {"groupId": "OG004", "value": "-2.40", "lowerLimit": "-2.74", "upperLimit": "-2.06"}, {"groupId": "OG005", "value": "-0.38", "lowerLimit": "-0.71", "upperLimit": "-0.05"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.003", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.03", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.51", "ciUpperLimit": "-0.56"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.57", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.04", "ciUpperLimit": "-1.09"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.68", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.16", "ciUpperLimit": "-1.21"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.78", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.26", "ciUpperLimit": "-1.30"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.741", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "0.24", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.24", "ciUpperLimit": "0.71"}]}, {"type": "SECONDARY", "title": "Baseline Systolic Blood Pressure", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.", "populationDescription": "All randomized participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "55"}, {"groupId": "OG003", "value": "55"}, {"groupId": "OG004", "value": "55"}, {"groupId": "OG005", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "126.7", "spread": "1.71"}, {"groupId": "OG001", "value": "126.5", "spread": "2.18"}, {"groupId": "OG002", "value": "127.9", "spread": "2.31"}, {"groupId": "OG003", "value": "125.8", "spread": "1.97"}, {"groupId": "OG004", "value": "124.9", "spread": "2.20"}, {"groupId": "OG005", "value": "126.6", "spread": "1.83"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic Blood Pressure at Week 12", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 12.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.55", "lowerLimit": "-2.55", "upperLimit": "1.44"}, {"groupId": "OG001", "value": "-2.69", "lowerLimit": "-4.63", "upperLimit": "-0.75"}, {"groupId": "OG002", "value": "-4.03", "lowerLimit": "-5.99", "upperLimit": "-2.07"}, {"groupId": "OG003", "value": "-3.43", "lowerLimit": "-5.43", "upperLimit": "-1.43"}, {"groupId": "OG004", "value": "-3.93", "lowerLimit": "-5.94", "upperLimit": "-1.91"}, {"groupId": "OG005", "value": "-1.09", "lowerLimit": "-3.05", "upperLimit": "0.87"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.163", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.13", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.92", "ciUpperLimit": "0.65"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.056", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-3.48", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.28", "ciUpperLimit": "-0.68"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.096", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.88", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.70", "ciUpperLimit": "-0.05"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.064", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-3.37", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.21", "ciUpperLimit": "-0.53"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.403", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.54", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.33", "ciUpperLimit": "2.26"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic Blood Pressure at Week 2", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 2.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 2", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "52"}, {"groupId": "OG002", "value": "49"}, {"groupId": "OG003", "value": "50"}, {"groupId": "OG004", "value": "49"}, {"groupId": "OG005", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.93", "lowerLimit": "-3.73", "upperLimit": "-0.12"}, {"groupId": "OG001", "value": "-2.30", "lowerLimit": "-4.08", "upperLimit": "-0.51"}, {"groupId": "OG002", "value": "-4.73", "lowerLimit": "-6.57", "upperLimit": "-2.89"}, {"groupId": "OG003", "value": "-2.28", "lowerLimit": "-4.10", "upperLimit": "-0.45"}, {"groupId": "OG004", "value": "-5.39", "lowerLimit": "-7.23", "upperLimit": "-3.55"}, {"groupId": "OG005", "value": "-0.91", "lowerLimit": "-2.74", "upperLimit": "0.91"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.425", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.37", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.91", "ciUpperLimit": "2.17"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.082", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.81", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.38", "ciUpperLimit": "-0.23"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.430", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.35", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.92", "ciUpperLimit": "2.21"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.043", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-3.47", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.05", "ciUpperLimit": "-0.89"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.694", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "1.01", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.55", "ciUpperLimit": "3.58"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic Blood Pressure at Week 4", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.57", "lowerLimit": "-4.31", "upperLimit": "-0.82"}, {"groupId": "OG001", "value": "-3.94", "lowerLimit": "-5.64", "upperLimit": "-2.25"}, {"groupId": "OG002", "value": "-5.15", "lowerLimit": "-6.86", "upperLimit": "-3.44"}, {"groupId": "OG003", "value": "-5.43", "lowerLimit": "-7.17", "upperLimit": "-3.69"}, {"groupId": "OG004", "value": "-3.33", "lowerLimit": "-5.09", "upperLimit": "-1.57"}, {"groupId": "OG005", "value": "-3.32", "lowerLimit": "-5.05", "upperLimit": "-1.60"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.234", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.38", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.81", "ciUpperLimit": "1.05"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.087", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.59", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.03", "ciUpperLimit": "-0.14"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.068", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.86", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.33", "ciUpperLimit": "-0.40"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.346", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.77", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.25", "ciUpperLimit": "1.71"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.346", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.76", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.21", "ciUpperLimit": "1.70"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic Blood Pressure at Week 8", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 8.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.44", "lowerLimit": "-2.42", "upperLimit": "1.55"}, {"groupId": "OG001", "value": "-1.53", "lowerLimit": "-3.46", "upperLimit": "0.40"}, {"groupId": "OG002", "value": "-2.85", "lowerLimit": "-4.80", "upperLimit": "-0.90"}, {"groupId": "OG003", "value": "-3.04", "lowerLimit": "-5.03", "upperLimit": "-1.06"}, {"groupId": "OG004", "value": "-3.30", "lowerLimit": "-5.31", "upperLimit": "-1.30"}, {"groupId": "OG005", "value": "-2.43", "lowerLimit": "-4.38", "upperLimit": "-0.48"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.306", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.10", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.87", "ciUpperLimit": "1.67"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.133", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.41", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.19", "ciUpperLimit": "0.37"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.117", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.61", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.42", "ciUpperLimit": "0.20"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.097", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.87", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.69", "ciUpperLimit": "-0.04"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.179", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.00", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.78", "ciUpperLimit": "0.79"}]}, {"type": "SECONDARY", "title": "Baseline Diastolic Blood Pressure", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.", "populationDescription": "All randomized participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "55"}, {"groupId": "OG003", "value": "55"}, {"groupId": "OG004", "value": "55"}, {"groupId": "OG005", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "79.14", "spread": "1.24"}, {"groupId": "OG001", "value": "78.95", "spread": "1.14"}, {"groupId": "OG002", "value": "78.19", "spread": "1.36"}, {"groupId": "OG003", "value": "78.45", "spread": "1.32"}, {"groupId": "OG004", "value": "78.61", "spread": "1.24"}, {"groupId": "OG005", "value": "79.15", "spread": "1.01"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Diastolic Blood Pressure at Week 12", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 12.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.81", "lowerLimit": "-0.41", "upperLimit": "2.02"}, {"groupId": "OG001", "value": "-1.12", "lowerLimit": "-2.30", "upperLimit": "0.06"}, {"groupId": "OG002", "value": "-1.01", "lowerLimit": "-2.20", "upperLimit": "0.18"}, {"groupId": "OG003", "value": "-3.18", "lowerLimit": "-4.40", "upperLimit": "-1.97"}, {"groupId": "OG004", "value": "-1.83", "lowerLimit": "-3.06", "upperLimit": "-0.61"}, {"groupId": "OG005", "value": "1.68", "lowerLimit": "0.49", "upperLimit": "2.87"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.072", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.93", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.62", "ciUpperLimit": "-0.24"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.086", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.81", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.51", "ciUpperLimit": "-0.11"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-3.99", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.71", "ciUpperLimit": "-2.27"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.025", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.64", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.37", "ciUpperLimit": "-0.92"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.746", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "0.88", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.82", "ciUpperLimit": "2.58"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Diastolic Blood Pressure at Week 2", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 2.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 2", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "52"}, {"groupId": "OG002", "value": "49"}, {"groupId": "OG003", "value": "50"}, {"groupId": "OG004", "value": "49"}, {"groupId": "OG005", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.57", "lowerLimit": "-1.69", "upperLimit": "0.56"}, {"groupId": "OG001", "value": "-1.25", "lowerLimit": "-2.37", "upperLimit": "-0.14"}, {"groupId": "OG002", "value": "-1.26", "lowerLimit": "-2.41", "upperLimit": "-0.12"}, {"groupId": "OG003", "value": "-1.97", "lowerLimit": "-3.11", "upperLimit": "-0.84"}, {"groupId": "OG004", "value": "-3.01", "lowerLimit": "-4.16", "upperLimit": "-1.86"}, {"groupId": "OG005", "value": "0.92", "lowerLimit": "-0.22", "upperLimit": "2.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.289", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.69", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.27", "ciUpperLimit": "0.90"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.288", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.70", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.31", "ciUpperLimit": "0.91"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.130", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.41", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.01", "ciUpperLimit": "0.19"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.026", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.44", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.05", "ciUpperLimit": "-0.84"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.883", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "1.49", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.11", "ciUpperLimit": "3.08"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Diastolic Blood Pressure at Week 4", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.80", "lowerLimit": "-1.80", "upperLimit": "0.21"}, {"groupId": "OG001", "value": "-2.47", "lowerLimit": "-3.44", "upperLimit": "-1.49"}, {"groupId": "OG002", "value": "-3.08", "lowerLimit": "-4.07", "upperLimit": "-2.10"}, {"groupId": "OG003", "value": "-2.81", "lowerLimit": "-3.81", "upperLimit": "-1.80"}, {"groupId": "OG004", "value": "-2.10", "lowerLimit": "-3.11", "upperLimit": "-1.09"}, {"groupId": "OG005", "value": "-0.51", "lowerLimit": "-1.51", "upperLimit": "0.48"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.063", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.67", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.07", "ciUpperLimit": "-0.27"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.019", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.29", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.69", "ciUpperLimit": "-0.88"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.035", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.01", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.43", "ciUpperLimit": "-0.59"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.121", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.30", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.73", "ciUpperLimit": "0.12"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.602", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "0.29", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.13", "ciUpperLimit": "1.70"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Diastolic Blood Pressure at Week 8", "description": "Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 8.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.80", "lowerLimit": "-0.40", "upperLimit": "1.99"}, {"groupId": "OG001", "value": "-1.40", "lowerLimit": "-2.56", "upperLimit": "-0.24"}, {"groupId": "OG002", "value": "-0.69", "lowerLimit": "-1.86", "upperLimit": "0.48"}, {"groupId": "OG003", "value": "-2.23", "lowerLimit": "-3.42", "upperLimit": "-1.04"}, {"groupId": "OG004", "value": "-1.20", "lowerLimit": "-2.40", "upperLimit": "0.01"}, {"groupId": "OG005", "value": "0.32", "lowerLimit": "-0.85", "upperLimit": "1.49"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.045", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-2.20", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.86", "ciUpperLimit": "-0.54"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.126", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.49", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.16", "ciUpperLimit": "0.18"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.011", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-3.03", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.72", "ciUpperLimit": "-1.34"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.066", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-1.99", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.69", "ciUpperLimit": "-0.30"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.357", "pValueComment": "P-value is one-sided.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-0.48", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.15", "ciUpperLimit": "1.19"}]}, {"type": "SECONDARY", "title": "Baseline Fasting Plasma Glucose", "description": "Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "populationDescription": "All randomized participants.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "55"}, {"groupId": "OG003", "value": "55"}, {"groupId": "OG004", "value": "55"}, {"groupId": "OG005", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "165.3", "spread": "5.65"}, {"groupId": "OG001", "value": "162.5", "spread": "6.75"}, {"groupId": "OG002", "value": "156.5", "spread": "5.79"}, {"groupId": "OG003", "value": "163.3", "spread": "6.30"}, {"groupId": "OG004", "value": "171.3", "spread": "7.69"}, {"groupId": "OG005", "value": "166.2", "spread": "6.70"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 12", "description": "The change from baseline is the Week 12 FPG minus the Week 0 fasting plasma glucose (LOCF). Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 12.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.76", "lowerLimit": "-2.47", "upperLimit": "8.00"}, {"groupId": "OG001", "value": "-18.23", "lowerLimit": "-23.32", "upperLimit": "-13.14"}, {"groupId": "OG002", "value": "-23.06", "lowerLimit": "-28.21", "upperLimit": "-17.90"}, {"groupId": "OG003", "value": "-31.47", "lowerLimit": "-36.71", "upperLimit": "-26.24"}, {"groupId": "OG004", "value": "-29.26", "lowerLimit": "-34.58", "upperLimit": "-23.94"}, {"groupId": "OG005", "value": "-17.29", "lowerLimit": "-22.43", "upperLimit": "-12.15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-20.99", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.29", "ciUpperLimit": "-13.69"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided.P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-25.82", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-33.17", "ciUpperLimit": "-18.47"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-34.23", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-41.64", "ciUpperLimit": "-26.83"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-32.02", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-39.49", "ciUpperLimit": "-24.56"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-20.05", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-27.39", "ciUpperLimit": "-12.72"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 2", "description": "The change from baseline is the Week 2 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 2.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 2", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "51"}, {"groupId": "OG002", "value": "49"}, {"groupId": "OG003", "value": "50"}, {"groupId": "OG004", "value": "49"}, {"groupId": "OG005", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.89", "lowerLimit": "0.50", "upperLimit": "11.27"}, {"groupId": "OG001", "value": "-15.07", "lowerLimit": "-20.46", "upperLimit": "-9.69"}, {"groupId": "OG002", "value": "-15.68", "lowerLimit": "-21.19", "upperLimit": "-10.17"}, {"groupId": "OG003", "value": "-26.65", "lowerLimit": "-32.09", "upperLimit": "-21.21"}, {"groupId": "OG004", "value": "-16.44", "lowerLimit": "-21.97", "upperLimit": "-10.91"}, {"groupId": "OG005", "value": "-14.69", "lowerLimit": "-20.07", "upperLimit": "-9.30"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-20.96", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.58", "ciUpperLimit": "-13.34"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-21.57", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-29.27", "ciUpperLimit": "-13.86"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-32.54", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-40.20", "ciUpperLimit": "-24.88"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-22.33", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.05", "ciUpperLimit": "-14.61"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-20.57", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.19", "ciUpperLimit": "-12.96"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 4", "description": "The change from baseline is the Week 4 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 4", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.17", "lowerLimit": "0.10", "upperLimit": "10.24"}, {"groupId": "OG001", "value": "-16.91", "lowerLimit": "-21.84", "upperLimit": "-11.99"}, {"groupId": "OG002", "value": "-22.77", "lowerLimit": "-27.77", "upperLimit": "-17.78"}, {"groupId": "OG003", "value": "-27.95", "lowerLimit": "-33.02", "upperLimit": "-22.88"}, {"groupId": "OG004", "value": "-26.62", "lowerLimit": "-31.77", "upperLimit": "-21.46"}, {"groupId": "OG005", "value": "-18.00", "lowerLimit": "-22.98", "upperLimit": "-13.03"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-22.09", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-29.16", "ciUpperLimit": "-15.01"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-27.94", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-35.06", "ciUpperLimit": "-20.83"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-33.12", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-40.29", "ciUpperLimit": "-25.95"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-31.79", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-39.02", "ciUpperLimit": "-24.56"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-23.17", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-30.28", "ciUpperLimit": "-16.07"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 8", "description": "The change from baseline is the Week 8 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "populationDescription": "Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 8.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "80% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "50"}, {"groupId": "OG005", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.82", "lowerLimit": "-1.06", "upperLimit": "8.69"}, {"groupId": "OG001", "value": "-18.25", "lowerLimit": "-22.99", "upperLimit": "-13.51"}, {"groupId": "OG002", "value": "-24.69", "lowerLimit": "-29.49", "upperLimit": "-19.89"}, {"groupId": "OG003", "value": "-31.59", "lowerLimit": "-36.46", "upperLimit": "-26.71"}, {"groupId": "OG004", "value": "-30.99", "lowerLimit": "-35.94", "upperLimit": "-26.04"}, {"groupId": "OG005", "value": "-18.93", "lowerLimit": "-23.71", "upperLimit": "-14.15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-22.07", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.87", "ciUpperLimit": "-15.27"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-28.51", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-35.35", "ciUpperLimit": "-21.67"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-35.40", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-42.30", "ciUpperLimit": "-28.51"}, {"groupIds": ["OG000", "OG004"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-34.81", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-41.76", "ciUpperLimit": "-27.86"}, {"groupIds": ["OG000", "OG005"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.000", "pValueComment": "P-value is one-sided. P-value is rounded to 3 decimals; therefore, p \\<0.0005 is reported as 0.000.", "statisticalMethod": "ANCOVA", "statisticalComment": "ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.", "paramType": "Difference in least squares means", "paramValue": "-22.75", "ciPctValue": "80", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-29.58", "ciUpperLimit": "-15.92"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving HbA1c <7% at Week 12", "description": "Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "populationDescription": "Analysis population excludes participants with missing Week 12 HbA1c measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "50"}, {"groupId": "OG002", "value": "49"}, {"groupId": "OG003", "value": "44"}, {"groupId": "OG004", "value": "47"}, {"groupId": "OG005", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15.6"}, {"groupId": "OG001", "value": "44.0"}, {"groupId": "OG002", "value": "42.9"}, {"groupId": "OG003", "value": "38.6"}, {"groupId": "OG004", "value": "36.2"}, {"groupId": "OG005", "value": "43.1"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving HbA1C <6.5% at Week 12", "description": "Laboratory measurements were performed after an overnight fast \u22658 hours in duration.", "populationDescription": "Analysis population excludes participants with missing Week 12 HbA1c measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "50"}, {"groupId": "OG002", "value": "49"}, {"groupId": "OG003", "value": "44"}, {"groupId": "OG004", "value": "47"}, {"groupId": "OG005", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.7"}, {"groupId": "OG001", "value": "12.0"}, {"groupId": "OG002", "value": "20.4"}, {"groupId": "OG003", "value": "13.6"}, {"groupId": "OG004", "value": "14.9"}, {"groupId": "OG005", "value": "25.5"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Experienced an Advere Event (AE)", "description": "An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin.", "populationDescription": "All participants who received at least 1 dose of treatment (including sponsor-supplied metformin).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to 98 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}, {"id": "OG006", "title": "Metformin Run-in", "description": "Participants received open-label metformin during the run-in period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "55"}, {"groupId": "OG003", "value": "55"}, {"groupId": "OG004", "value": "55"}, {"groupId": "OG005", "value": "55"}, {"groupId": "OG006", "value": "375"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "29"}, {"groupId": "OG004", "value": "28"}, {"groupId": "OG005", "value": "30"}, {"groupId": "OG006", "value": "82"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Discontinued Study Medication Due to an AE", "description": "An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin and excludes a temporary discontinuation of study medication.", "populationDescription": "All participants who received at least 1 dose of treatment (including sponsor-supplied metformin).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to 84 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days"}, {"id": "OG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days"}, {"id": "OG006", "title": "Metformin Run-in", "description": "Participants received open-label metformin during the run-in period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "54"}, {"groupId": "OG002", "value": "55"}, {"groupId": "OG003", "value": "55"}, {"groupId": "OG004", "value": "55"}, {"groupId": "OG005", "value": "55"}, {"groupId": "OG006", "value": "375"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "2"}, {"groupId": "OG004", "value": "1"}, {"groupId": "OG005", "value": "1"}, {"groupId": "OG006", "value": "3"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 24 weeks (including 10-week run-in period, 12-week treatment period, and 2-week follow-up period).", "description": "Data presented below include the metformin run-in group (run-in period), 6 treatment groups (treatment period) and no upper limit on the follow-up window for participants who discontinued study drug.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days", "seriousNumAffected": 0, "seriousNumAtRisk": 54, "otherNumAffected": 13, "otherNumAtRisk": 54}, {"id": "EG001", "title": "Ertugliflozin 1 mg", "description": "Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days", "seriousNumAffected": 0, "seriousNumAtRisk": 54, "otherNumAffected": 10, "otherNumAtRisk": 54}, {"id": "EG002", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days", "seriousNumAffected": 2, "seriousNumAtRisk": 55, "otherNumAffected": 14, "otherNumAtRisk": 55}, {"id": "EG003", "title": "Ertugliflozin 10 mg", "description": "Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days", "seriousNumAffected": 0, "seriousNumAtRisk": 55, "otherNumAffected": 14, "otherNumAtRisk": 55}, {"id": "EG004", "title": "Ertugliflozin 25 mg", "description": "Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days", "seriousNumAffected": 1, "seriousNumAtRisk": 55, "otherNumAffected": 10, "otherNumAtRisk": 55}, {"id": "EG005", "title": "Sitagliptin 100 mg", "description": "Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days", "seriousNumAffected": 1, "seriousNumAtRisk": 55, "otherNumAffected": 12, "otherNumAtRisk": 55}, {"id": "EG006", "title": "Metformin Run-in", "description": "Participants received open-label metformin during the run-in period.", "seriousNumAffected": 2, "seriousNumAtRisk": 375, "otherNumAffected": 30, "otherNumAtRisk": 375}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 375}]}, {"term": "Food allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 375}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 375}]}, {"term": "Syncope", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 375}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 375}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 375}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 3, "numAffected": 3, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 4, "numAffected": 4, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 14, "numAffected": 14, "numAtRisk": 375}]}, {"term": "Genital infection fungal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 4, "numAffected": 3, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 2, "numAffected": 2, "numAtRisk": 375}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 3, "numAffected": 3, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 2, "numAffected": 2, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 375}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 5, "numAffected": 5, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 2, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 4, "numAffected": 4, "numAtRisk": 375}]}, {"term": "Blood pressure increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 3, "numAffected": 3, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 375}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 5, "numAffected": 5, "numAtRisk": 375}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 6, "numAffected": 6, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 4, "numAffected": 4, "numAtRisk": 375}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 3, "numAffected": 3, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 1, "numAffected": 1, "numAtRisk": 375}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 54}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 55}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 55}, {"groupId": "EG006", "numEvents": 4, "numAffected": 4, "numAtRisk": 375}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to the Sponsor at least 30-days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada", "India", "Korea, Republic of", "Mexico", "Puerto Rico", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M5114", "name": "Body Weight", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "C000570288", "term": "Ertugliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Game", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M263808", "name": "Ertugliflozin", "asFound": "True", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}